10224 FALLS ROAD, POTOMAC, MD
Stock Purchase Agreements with CEO Ram Mukunda and PFO Claudia Grimaldi
IGC Pharma, Inc. Extends Master Loan and Security Agreement with O-Bank
IGC Pharma Enters $346,910 Securities Purchase Agreement with FirstFire
IGC Pharma Enters $353,050 Securities Purchase Agreement with VFG
IGC Pharma Enters $234K Subscription Agreement for Common Stock
IGC Pharma, Inc. Changes Fiscal Year-End to December 31
IGC Pharma, Inc. Increases Authorized Common Stock to 600 Million Shares
Company Announces Completion of Disposition of Manufacturing Equipment and Inventory
Q4
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload